Addison Disease, Autoimmune Diseases, Celiac Disease, Graves Disease, Hashimoto Disease, Type 1 Diabetes, Vitiligo
Conditions
Keywords
Type 1 diabetes, Autoimmune Diseases, Pediatrics, Children, Adolescents
Brief summary
This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents. It also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of France's centers of reference for paediatric diabetes.
Interventions
OTHERNo intervention.
There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with type 1 diabetes diagnosed with the following criteria: (i) Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ICA, GAD, IA2, IAA and/or ZnT8 * age \< 18 years old at type 1 diabetes diagnostic * type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01
Exclusion criteria
* type 1 diabetes diagnostic not certain
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of additional autoimmune diseases at type 1 diabetes diagnosis | up to 3 weeks after type 1 diabetes diagnosis | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
| Type of additional autoimmune diseases at type 1 diabetes diagnosis | up to 3 weeks after type 1 diabetes diagnosis | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurence or non-occurence of each type of additional autoimmune disease during follow-up | From type 1 diabetes diagnostic to last news date, an average of 3 years | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations, in this outcome studied each one separately |
| Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
| Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
| Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
| Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease | From type 1 diabetes diagnosis to last news date, from 1 to 6 years | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
| Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5 | From type 1 diabetes diagnosis to last news date, from 1 to 6 years | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
| Characteristics of patients, if additional autoimmune disease is present or absent | up to 3 weeks after type 1 diabetes diagnosis | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic |
| Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes | during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years | presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases |
| If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease | From type 1 diabetes diagnosis to last news date, from 1 to 6 years | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) |
| If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction | Up to 3 weeks after type 1 diabetes diagnosis | Thyroid dysfunction : hormonal dysfunction associated to Hashimoto |
| Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto | From type 1 diabetes diagnosis to last news date, from 1 to 6 years | Occurence during type 1 diabetes follow-up of thyroid dysfunction in patients with Hashimoto |
| Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment | Up to 3 weeks after type 1 diabetes diagnosis | — |
| Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto | From type 1 diabetes diagnosis to last news date, from 1 to 6 years | — |
| Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes | Up to 3 weeks after type 1 diabetes diagnosis | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic, presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases |
| Occurence or non-occurence of at least one additional autoimmune diseases during follow-up | From type 1 diabetes diagnostic to last news date, an average of 3 years | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
Countries
France
Outcome results
None listed